The company has received approval for conducting a clinical trial of stem cell therapy in patients affected with mild to severe Parkinson’s disease.

TOP INSIGHT
Parkinson’s Disease is the second most common neurodegenerative disease and affects over seven million people worldwide. Currently, there is no cure, but a new stem cell therapy conducted in Australia increases the hopes for a treatment.
Researchers will implant replacement brain cells, called as neural precursor cells which will finish maturing in the brain into the kind of neurons destroyed by the movement disorder. These neuronal cells will be derived from the company’s parthenogenetic stem cells, which are produced from unfertilized human egg cells.
The trial will happen at the Royal Melbourne Hospital and will involve between 30 and 70 million neural cells being implanted into the participants’ brains.
“We are very pleased to start the first human study of ISC-hpNSC's for the treatment of this debilitating disease. There is a large unmet medical need for new treatments that may halt or reverse the progression of Parkinson's disease and we believe our human neural stem cells may fill this need for the millions of people with this disease. We look forward to reporting on the progress of the clinical trial over the coming months,” said Andrey Semechkin, ISCO chief executive officer.
Source-Medindia
MEDINDIA




Email










